Table 1.
Summary of longitudinal publications meeting inclusion criteria and included in the systematic literature review
| Author | Study name | Publication year | Overall sample size (n) | Sample size of smallest sub-group (n) | Mean follow-up (years) | Country | Overall quality assessment score (%)a,b |
|---|---|---|---|---|---|---|---|
| Afghahi et al. [22] | Swedish National Diabetes Register | 2010 | 3667 | 407 | 5 | Sweden | 18 (67%) |
| Afkarian et al. [9] | NHANES III | 2013 | 1430 | 658 | 10 | USA | 17 (63%) |
| Al Suleiman et al. [77] | N/A | 2008 | 35 | N/A | 8 | Saudi Arabia | 16 (59%) |
| Altemtam et al. [23] | N/A | 2011 | 270 | 94 | 5.2 | UK | 13 (48%) |
| Alwakeel et al. [44] | N/A | 2011 | 621 | 166 | 10 | Saudi Arabia | 12 (44%) |
| Andresdottir et al. [10] | N/A | 2014 | 543 | 286 | 5.7 | Denmark | 15 (56%) |
| Araki et al. [49] | Japanese Elderly Diabetes Intervention Trial | 2012 | 621 | 306 | 4.3 | Japan | 15 (56%) |
| Azubike et al. [56] | N/A | 2013 | 22 | N/A | 12 | Nigeria | 15 (56%) |
| Bentata et al. [24] | N/A | 2014 | 144 | 26 | 4.1 | Morocco | 13 (48%) |
| Berhane et al. [25] | N/A | 2011 | 2420 | 1503 | 10.2 | USA | 15 (56%) |
| Bruno et al. [26] | Casale Monferrato Study | 2007 | 1538 | 21 | 11 | Italy | 19 (70%) |
| Chen et al. [27] | N/A | 2012 | 487 | 65 | 6.6 | Taiwan | 16 (59%) |
| Cox et al. [28] | Diabetes Heart Study | 2013 | 1220 | N/A | 8.2 | USA | 17 (63%) |
| De Cosmo et al. [8] | N/A | 2015 | 13,964 | 2540 | 4 | Italy | 20 (74%) |
| de Hauteclocque et al. [37] | SURDIAGENE | 2014 | 1146 | 486 | 5.7 | France | 19 (70%) |
| Dunkler et al. [29] | ONTARGET and ORIGIN | 2015 | 15,066 | 6766 | 5.5 | Multinational | 15 (56%) |
| Elley et al. [38] | New Zealand Diabetes Cohort Study | 2013 | 31,613 | 5877 | 7.3 | New Zealand | 16 (59%) |
| Jardine et al. [39] | ADVANCE | 2012 | 11,140 | 7377 | 4.8 | Multinational | 19 (70%) |
| Kitai et al. [30] | N/A | 2015 | 125 | 22 | 75 days | Japan | 20 (74%) |
| Lambers Heerspink et al. [50] | RENAAL | 2010 | 701 | N/A | 3.4 | Multinational | 16 (59%) |
| Monseu et al. [40] | SURDIAGENE | 2015 | 1371 | 411 | 4.8 | France | 15 (56%) |
| Moriya et al. [54] | N/A | 2012 | 30 | 9 | 6.2 | Japan | 14 (52%) |
| Murussi et al. [31] | N/A | 2007 | 173 | 41 | 8 | Brazil | 17 (63%) |
| Packham et al. [11] | N/A | 2012 | 3228 | N/A | 2.8 | Multinational | 19 (70%) |
| Pavkov et al. [12] | N/A | 2008 | 983 | N/A | 8.4 | USA | 17 (63%) |
| Pavkov et al. [45] | N/A | 2012 | 195 | 88 | 4 | USA | 15 (56%) |
| Pavkov et al. [41] | N/A | 2013 | 234 | 76 | 10.7 | USA | 16 (59%) |
| Retnakaran et al. [13] | UKPDS | 2006 | 9063 | 4031 | 15 | UK | 17 (63%) |
| Sinkeler et al. [42] | RENAAL and IDNT | 2013 | 1872 | 623 | 3 | Multinational | 14 (52%) |
| Stoycheff et al. [52] | IDNT | 2009 | 1608 | 693 | 2.6 | Multinational | 14 (52%) |
| Takagi et al. [46] | N/A | 2015 | 1802 | 1655 | 6.9 | Japan | 18 (67%) |
| Tanaka et al. [47] | N/A | 2015 | 3231 | 137 | 5.9 | Japan | 19 (70%) |
| Targher et al. [32] | Verona Diabetes Study | 2011 | 2823 | 38 | 5.7 | Italy | 19 (70%) |
| Unsal et al. [33] | N/A | 2012 | 122 | 35 | 3.3 | Turkey | 15 (56%) |
| Viana et al. [34] | N/A | 2012 | 199 | 86 | 6.1 | Brazil | 15 (56%) |
| Vupputuri et al. [35] | N/A | 2011 | 10,290 | 52 | 3.1 | USA | 17 (63%) |
| Wada et al. [48] | N/A | 2013 | 4328 | 534 | 7 | Japan | 19 (70%) |
| Yang et al. [36] | Hong Kong Diabetes Registry | 2006 | 4438 | 159 | 2.9 | Hong Kong | 19 (70%) |
| Yokoyama et al. [53] | JDDM | 2011 | 2954 | 175 | 3.8 | Japan | 16 (59%) |
| Yokoyama et al. [55] | N/A | 2012 | 211 | 28 | 4.5 | Japan | 18 (67%) |
| Yokoyama et al. [51] | N/A | 2013 | 1002 | 303 | 3.8 | Japan | 16 (59%) |
| Zoppini et al. [43] | Verona Diabetes Study | 2012 | 1682 | 263 | 10 | Italy | 19 (70%) |
NHANES III Third National Health and Nutrition Examination Survey, SURDIAGENE Survie, Diabete de type 2 et Genetique Study, ONTARGET Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial, ORIGIN Outcome Reduction With Initial Glargine Intervention Trial, ADVANCE Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation Study, RENAAL Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan Study, UKPDS UK Prospective Diabetes Study, IDNT Irbesartan Diabetic Nephropathy Trial, JDDM Japan Diabetes Clinical Data Management Study
aScored using the Downs and Black quality assessment instrument [21]
bProportional score was calculated by dividing each study’s overall quality assessment score by the sum of points available in the Downs and Black instrument